Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accounts Payables (2016 - 2025)

Voyager Therapeutics' Accounts Payables history spans 11 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 25.45% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 25.45%, while the annual FY2025 figure was $5.0 million, 25.45% up from the prior year.
  • Accounts Payables for Q4 2025 was $5.0 million at Voyager Therapeutics, up from $2.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.6 million in Q1 2024 and bottomed at $574000.0 in Q4 2021.
  • The 5-year median for Accounts Payables is $2.3 million (2022), against an average of $2.5 million.
  • The largest annual shift saw Accounts Payables tumbled 82.52% in 2021 before it soared 347.04% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $574000.0 in 2021, then skyrocketed by 347.04% to $2.6 million in 2022, then plummeted by 37.49% to $1.6 million in 2023, then surged by 149.13% to $4.0 million in 2024, then rose by 25.45% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Accounts Payables are $5.0 million (Q4 2025), $2.1 million (Q3 2025), and $1.8 million (Q2 2025).